PolyPid (NASDAQ:PYPD) Price Target Lowered to $11.00 at HC Wainwright

PolyPid (NASDAQ:PYPD) had its price objective decreased by HC Wainwright from $14.00 to $11.00 in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Craig Hallum initiated coverage on shares of PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price target on the stock.

PolyPid Trading Down 4.0 %

Shares of NASDAQ PYPD opened at $2.85 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. PolyPid has a 12 month low of $2.37 and a 12 month high of $9.20. The company has a market cap of $13.67 million, a price-to-earnings ratio of -0.36 and a beta of 1.33. The business has a fifty day simple moving average of $3.26 and a 200-day simple moving average of $3.53.

Institutional Investors Weigh In On PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC acquired a new position in shares of PolyPid Ltd. (NASDAQ:PYPD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid as of its most recent SEC filing. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.